In this prospective randomized trial we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive CLL. Study end points were complete response (CR), overall response, minimal residual disease (MRD), progression-free survival, overall survival and toxicity. From January 1st 1998 to December 31st 2003, 508 patients from 15 hematology departments were randomized. Compared to 2-CdA, CMC induced higher CR rate (36% vs. 21%, p=0.004), whilst only trend for higher CR rate with CC was observed (29% vs. 21%, p=0.08). Furthermore, percentage of patients in CR and MRD negative were higher in CMC compared to 2-CdA (23% vs. 14% p=0.042). There were no differences in overall response, progression-free survival and overall survival among treatment groups. Grade 3/4 neutropenia occurred more frequently in CC (32%) and CMC (38%) than in 2-CdA (20%) (p=0.01 and p=0.004, respectively). Infections were more frequent in CMC compared to 2-CdA (40% vs. 27%, p=0.02). In conclusion, CMC used in first-line treatment of CLL gives higher CR rate and suppresses MRD more efficiently than 2-CdA monotherapy, although associates with increased toxicity. No important differences in efficacy and toxicity were found between CC and 2-CdA regimens.
Introduction
Chronic lymphocytic leukemia (CLL) is a malignant disease characterized by an accumulation of mature monoclonal B-cells in the blood, bone marrow, spleen and liver (1, 2) . The disease is diagnosed most commonly in the elderly (median age 65 years) with only 10-15% of patients under the age of 55 years (3) . Management is determined by the stage and activity of the disease with chemotherapy not normally indicated in early and stable disease (4) . Moreover, one third of patients never requires treatment and dies from causes unrelated to CLL (5) . The remaining patients, with more advanced disease required a therapeutic intervention.
For many years, chlorambucil (Chl) has been considered the drug of choice for first-line therapy of CLL. Chl gives initial overall response rates (ORR) of 60% to 90% with a complete response (CR) in up to 20% of all patients (6, 7) . More recently, treatment approaches have included purine nucleoside analogues (PNA), fludarabine (FA), cladribine (2-CdA, 2-chlorodeoxyadenosine) and pentostatin (2'-deoxycoformycin, DCF), which seem to be the treatment of choice for patients failing Chl therapy (7) . Moreover, the role of PNA monotherapy as a first-line treatment of CLL has been investigated in randomized studies and the results have recently been published (8) (9) (10) (11) . These studies, including our randomized comparison of 2-CdA to Chl (11) , have shown a higher ORR and CR rate in patients treated with PNA monotherapy compared with alkylating agents monotherapy, but the overall survival (OS) rates were similar.
Some clinical reports suggest that the combination of PNA with other cytotoxic drugs may increase the CR and ORR and possibly suppress minimal residual disease (MRD) and prolong survival (12) (13) (14) (15) . Among cytotoxic agents, alkylating drugs and anthracyclines, e.g. mitoxantrone (MIT), were the primary candidates for use in combination with PNA. In our previous phase II studies we showed that combined treatment with 2-CdA and CY (CC regimen) or with 2-CdA, CY and MIT (CMC regimen) gave high ORR and CR and acceptable toxicity in previously untreated patients with CLL (16, 17) .
In this report we present the results of a prospective, randomized multicenter trial comparing the efficacy and toxicity of CC and CMC combination regimens to 2-CdA alone.
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Patients and methods

Criteria for eligibility
Patients with previously untreated progressive CLL, aged more than 18 years, were enrolled to the study. Diagnosis of CLL was established according to the National Cancer Institute -Sponsored Working Group (NCI-WG) recommended criteria (18) . The clinical stage of the disease was determined according to the modified Rai's classification (19, 20) . Progressive CLL was defined as CLL in all patients with Rai's stage III and IV or CLL in those patients with stage 0, I and II who fulfilled at least one of the following criteria: progressive lymphocytosis (doubling time shorter than 6 months), massive splenomegaly or bulky lymphadenopathy, recurrent disease-related infections, weight loss above 10% over a 6 month period, fever of 
Randomization procedure and treatment modality
Central randomization was performed in the Department of Hematology Medical University of Lodz, and the participating centers were informed about treatment assignment by phone, fax or e-mail. Eligible patients were randomly assigned to the one of the three following treatments:
1. Cladribine (2-CdA) administered at a dose 0.12 mg/kg in 2-h i.v. infusion for 5 days 2. CC protocol (2-CdA at a dose 0.12 mg/kg in 2-h i.v. infusion for 3 days + CY 650 mg/m 2 i.v. on day 1). (11, 16, 17) . Regarding CMC, three-day protocol was selected for this study based on our previous results (17) . We showed that three-day schedule (previously referenced as CMC3) has similar efficacy and lower toxicity than five-day CMC (CMC5) (17) .
The cycles were repeated every 28 days, for up to six courses. The response according to NCI-WG criteria (18) was initially assessed after administration of three courses of the assigned treatment. In patients who achieved CR after three cycles the treatment was stopped. In patients with partial response (PR) the treatment was continued until maximal response for up to three additional courses. If no response or progression of the disease was observed after first three cycles, the treatment was discontinued.
If hematological complications (thrombocytopenia below 50x10 
Study end points, response and toxicity criteria
The primary end point of the study was CR achieved after administration of at least three initial courses of one of the assigned treatments. The secondary end points were rate of CR with MRD negativity, ORR, progression free survival (PFS), OS and treatment-related toxicity.
Treatment effects and toxicity were monitored by physical examination, blood count evaluation, bone marrow aspiration and biopsy. Guidelines for response were those developed by the NCI-WG (18) . CR required the absence of symptoms and organomegaly, a completely normal blood cell count (absolute lymphocytes count < 4 
Flow cytometry assessment of residual disease
Immunophenotyping of peripheral blood and bone marrow was performed initially in all patients, and after treatment, in patients with CR by dual color flow cytometry as described by Brugiatelli et al. (23) . Presence of MRD in patients who achieved CR was defined as detection of more than 10% cells co-expressing CD5/CD19 and CD5/CD20 with monotypic light -chain expression of the total Blymphocyte population according to the criteria developed by Robertson et al (24) .
For
Statistical analysis
Preliminary data has suggested that a 25% CR might be expected with 2-CdA and thus sample size estimation was calculated on the assumption of a treatment benefit of 15% in the CR rate with either the CMC or CC regimen. Based on error levels of =0.05 and = 0.01 for a two-sided test, 140 patients were required to be assigned to each of the treatment groups. Taking into account possible drop-outs, accrual was increased by 20% resulting in a requirement of 168 patients per randomization arm.
Treatment groups were compared using either the Kruskal-Wallis or MannWhitney test for continuous data, and the Chi-Squared or Fisher's Exact test for categorical data. The influence of different variables, including type of chemotherapy, on the probability of achieving a response was analyzed initially by a Chi-squared test, and then by logistic regression analysis to find independent factors. PFS and OS curves were plotted using the Kaplan-Meier method (25) . Probabilities of PFS and OS were compared between groups by the log-rank test (26) . A multivariate analysis of potential prognostic factors influencing PFS and OS was performed using a Cox regression model. For each analysis a p< 0.05 was considered statistically significant. Table 2 .
Results
Patient characteristics
Median number of courses administered in 2-CdA arm was 5, while in CC and CMC arms median number of courses administered was 3. The treatment was stopped because of CR achievement after 3 cycles, as planned in the design of the study, in 10%, 13% and 26% of patients assigned to 2-CdA, CC and CMC arm, respectively. The treatment was discontinued due to NR or progressive disease after three courses in 14% of patients in 2-CdA arm, 12 % of patients in CC arm, and in 14% of patients in CMC arm. Treatment-related toxicity was the reason of earlier treatment withdrawal in 4%, 6% and 2% of all patients randomized to 2-CdA, CC and CMC arm, respectively. The median time between courses was 31 days in all treatment groups. Six courses of treatment were given in 49% of patients in 2-CdA arm, 35% of patients in CC arm, and in 26% of subjects assigned to CMC arm. 
Progression free survival
The median PFS in the whole group was 23.5 months (95% CI 
Overall survival
The median time of OS in all patients was 56 months (95% CI, 49.2-62.8). Of the 479 patients analyzed 173 (39%) have died with 64 (39%), 51 (32%), and 57 (38%) in the 2-CdA, CC and CMC groups respectively. The most frequent causes of death were disease progression and infectious complications (Table 5 ).
There was no significant differences in survival probabilities between the three treatment arms (p=0.73). The median OS time for the 2-CdA group was 51.2 months (95% CI, 40.7-61.8), whilst for the CC and CMC groups the medians have not yet been reached (Fig 2) . There were also no differences in OS between the treatment groups for patients in early Rai stages of CLL (p=0.6) and advanced stages of the disease (p=0.23) (data not shown). We have also not shown any statistically significant difference in the OS in patients treated with 2-CdA, CC or CMC aged less than 65 yrs (p=0.67), and patients aged 65 yrs or more (p=0.86) (data not shown).
The prognostic factors associated with longer OS in univariate analysis were age Table 4) .
Confirming the results of the univariate analysis, the type of randomly assigned therapy (CC and CMC compared to 2-CDA) had no influence on duration of OS.
Toxicity
Percentages of patients with grade 3/4 hematological and non-hematological toxicities according to randomization group are reported in Table 6 . In paired comparisons, neutropenia was more frequent in the CC and CMC arms (32% and 38%, respectively) compared with 2-CdA (19%) treated patients (p=0.01 and p=0.004 respectively). The percentages of thrombocytopenia were comparable between CMC and 2-CdA (24% vs. 19%, p=0.2) and CC and 2CdA (17% vs. 19%.p=0.4).
Interestingly, there was an increase in anemia rates in the 2-CdA group as compared to CMC group (13% and 9% respectively, p=0.02). The distribution of AIHA was similar in all three treatment groups: 11 patients (7%) in 2-CdA group, 13 (8%) in CC and 9 (6%) in CMC group (p=0.44).
Infections occurred more frequently in patients treated with CMC (40%) than with 2-CdA (27%) (p= 0.02), while the percentage of infections in the 2-CdA and CC arms was similar (27% and 34% respectively, p=0.2). Other side effects including Richter's syndrome were observed sporadically with similar incidences in all three groups. The difference in incidence of secondary neoplasm was not significant, although there was a trend to increased occurrence in combination treatment groups (p=0.32). We observed 2 secondary cancers in 2-CdA group (2 lung cancers), 6 secondary neoplasms in CC group (2 breast cancers, 2 lung cancers, 1 gastric carcinoma and 1 clear cell carcinoma of the kidney) and 7 secondary cancers in CMC group (3 lungs cancers, 2 gastric carcinoma, 1 clear cell carcinoma and 1 colon cancer) ( Table 6 ).
Discussion
In this multi-center prospective randomized study we compared CC and CMC combination chemotherapy to 2-CdA alone in previously untreated CLL. We found that the CMC regimen was more effective than 2-CdA alone in terms of CR achievement (36% vs. 21%, p=0.004) and achievement of CR with eradication of MRD (23.4% vs. 14.0% p=0.042), but did not increase ORR or prolonged response duration or overall survival of the CLL patients. Regarding the CC regimen, no increased response or survival advantage compared to 2-CdA could be detected. 
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Besides increased number of CR in CMC compared to 2-CdA arm, higher proportion of patients with CR and MRD negative is also of interest. However, it should be noted that at the time of the study initiation there was no consensus regarding assessment of MRD in CLL, and the applied by us two-color flow-cytometry method developed by Brugiatelli (23) , is certainly less sensitive than the recent fourcolor flow cytometry or molecular tests (27) . Moreover, we did not observe significant difference in number of patients MRD negative between CMC and 2-CdA when only CR patients were considered, that may mean that the tendency to achieve MRD Despite significant difference in CR rates, the median OS did not differ in patients treated with CMC as compared with 2-CdA treated group. This is in agreement with the results of other randomized trials comparing PNA with alkylators or with PNA-based combination, in which higher response rate, and even higher response duration, did not translate into longer OS (8) (9) (10) (11) 34) . It is likely that significant improvements in prognosis in CLL patients may be achieved when PNAs are combined with monoclonal antibodies, rituximab and potentially also alemtuzumab (28, (36) (37) (38) . The recent report of 2 phase study (CALGB 9712) comparing concurrent and sequential combination of FA and rituximab (FR) analysis strongly suggest that addition of rituximab to FA may prolong survival of CLL patients, this need to be confirmed in a direct phase 3 prospective trial because of potential confounding factors e.g. differences in supportive care. Furthermore, a single-institution study on FA, CY and rituximab combination (FCR) produced an exceptionally high CR rate of 70% with a projected PFS at 4 years of 69% in untreated CLL patients, thus inclusion of this regimen into multi-center phase 3 studies is warranted (38). In the context of these promising results of rituximab and FA combinations, it seems possible that incorporating rituximab into other PNAbased regimens e.g. CMC or CC may also be of clinical benefit for patients with CLL.
In our study CMC and CC regimens caused neutropenia more frequently than 2-CdA alone. Higher myelotoxicity of PNA in combination with other cytotoxic drugs was observed also in other studies (34,39,40). In a previous phase II trial we observed high myelotoxicity of CMC that was a reason of reduction of 2-CdA administration from 5 to 3 days in combined regimens in this study (17) . Similar reductions of PNA administration from 5 to 3 days when used in combination with CY or MIT were introduced in other studies (13 -15, 41) . We also found an increase in grade 3/4 infections in patients treated with CMC regimen (40%) than in patients treated with 2-CdA alone (27%, p=0.02), but no difference was found for the CC group (34%). It is likely that routine prophylactic administration of growth factor (G-CSF) would reduce an infection rate in CMC and CC programmes (42, 43) . Further decrease in treatment toxicity may probably be achieved by reduction of combination drug doses, but this approach could also compromise response. (44, 45) .
In conclusion, we found that the CMC regimen used for the treatment of progressive CLL, gives a higher complete response rate and higher complete response rate with negative MRD than 2-CdA monotherapy, although does not prolong survival. Based on the results of our study, we believe that 2-CdA monotherapy has currently limited role in CLL treatment. High efficacy and For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
